Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 4 April 2017, 08:56 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Smell Identification Test UPSIT Series in Japan

TOKYO, Apr 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that the smell identification test "UPSIT Series" will be launched today for sale to health insurance pharmacies and local governments in Japan. The UPSIT Series was developed by Sensonics International. Eisai has obtained exclusive rights to market the test in Japan, and has modified it for the Japanese market.

The UPSIT Series' 4-Item Pocket Smell Test is a multiple-choice test comprised of four microencapsulated odorant strips attached to a thick sheet of paper. The scents are released by lightly scratching the strips with a cotton swab or other tool, after which the person taking the test must attempt to select the correct name of the scent from four options that are provided. In this way, smell identification ability can be determined in approximately 3 minutes.

The sense of smell is one of the important senses for detecting hazards in daily life, such as rotten food, poor hygiene, gas leakage, and fires. Olfactory function, which includes the ability to identify smells (identification) and to detect a faint smell (detection), is influenced by age, physical condition, memory, and psychological state. Persons are often unaware the changes in the ability to identify smells, subjectively. The UPSIT Series, which objectively measures smell identification ability, makes it possible to detect and track changes in physical condition and psychological state.

This test will most likely be used in counseling sessions, such as during health consultations or health promotion events held by health insurance pharmacies or local governments. Should the person taking the test make any mistakes, it may be recommended that they undertake a review of their lifestyle, including sleep, exercise, dietary and smoking habits, under the guidance of a pharmacist or other relevant person. Alternatively, a visit to an otolaryngologist or a primary care physician may be recommended. It is important to note that the UPSIT Series is not an alternative for proper medical examinations and diagnosis by qualified medical professionals.

Scents are made up of multiple chemical substances. The roof of the nasal cavity contains 5 million olfactory receptor cells, each of which reacts to certain chemical substances. These cells work in concert to transmit smell information to the brain. The transmitted information is then integrated with information stored in the brain, including learned information, making it possible to identify "a certain smell".

As one part of the hhc solutions business, Eisai has been engaged for many years in activities for "creating communities where senior citizens can live in peace of mind". In carrying out these activities, Eisai has identified real world needs and issues, also called "clinical questions". By providing solutions to these clinical questions, in cooperation with stakeholders including local governments, medical institutions and pharmacies, Eisai seeks to make further contributions to support health promotion and health management of senior citizens.

About smell identification test UPSIT Series

The UPSIT Series' 4-Item Pocket Smell Test is a multiple-choice test comprised of a four microencapsulated odorant strips attached to a thick sheet of perforated paper. The scents are released by lightly scratching the strips with a cotton swab or other tool, after which the person taking the test must attempt to select the correct scent name from four options. In this way, smell identification ability can be confirmed in approximately 3 minutes. Please note that UPSIT is not medicine or a medical device, and is not an alternative for proper medical examinations and diagnosis by qualified medical professionals. The UPSIT was developed by Richard L. Doty, professor and director the Smell and Taste Center within the Department of Otorhinolaryngology, University of Pennsylvania. Professor Doty also founded Sensonics. Inc. in 1982, and has markeded the UPSIT under the trade name Smell Identification Test worldwide since that time. Multiple products are being developed with different numbers and types of scents.

The Pocket Smell Test contains a set of four scents for the person being tested to identify, including cool scents (minty etc.), sweet scents (strawberry etc.) and unpleasant scents (gas etc.). There are two versions of the 4-Item Pocket Smell Test available, both of which make use of four different scents.

About Sensonics International

Sensonics International, whose headquarters are located in Haddon Heights, NJ, USA, was founded in 1982 and is the largest manufacturer and distributor of smell and taste tests in the world. In addition to marketing a range of smell and taste testing products, it provides industrial and medical consulting services, including the training of organoleptic panels for the food, flavor and fragrance industries, product evaluation, screening of smell function of workpalce employees, and a host of other chemosensation-related activities. Its tests have been administered to over a million people world wide and its flagship test, the UPSIT, has been translated into 30 different langauges.

About smells

Olfactory function, which includes the ability to identify smells (identification) and to detect a faint smell (detection), and detect is influenced by age, physical condition, memory, and psychological state. Since changes in olfactory ability are seldom reported as a subjective symptom, objective confirmation is neccessary. The roof of the nasal cavity is said to have 5 million olfactory cells. Each olfactory cell has one type of receptor, which binds with chemical substances of a matching affinity. A scent is made up of multiple chemical substances, and the bound receptors assemble this information, and transmit it to the brain. There, it is integrated with information stored in the brain, and identifed as "a certain smell". Olfactory disorders are divided into: Respiratory Dysosmia, where scents do not reach the olfactory cells, Olfactory Mucosa Dysosmia, where the olfactory cells and olfactory nerves are damaged, Combined Dysosmia, a combination of the aforementioned, and Central Dysosmia, where the olfactory center or surrounding pathways are damaged.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: